Klow Blend Research Guide

Neurological and gut-brain axis research stack

The Klow Blend combines Semax, KPV, and NAD+ into a single research preparation targeting neuroprotection, anti-inflammatory cascades, and cellular energy restoration. The three compounds operate through mechanistically distinct pathways that converge on themes of cellular stress resilience and gut-brain axis signaling.

3-compound blend Semax + KPV + NAD+

Gut-brain axis Primary research focus

Multi-pathway BDNF + NF-kB + sirtuin

What is Klow Blend?

The Klow Blend pairs three research compounds in a single lyophilized vial. Semax is the Russian-developed heptapeptide ACTH 4-10 analogue, with strong neurotrophin upregulation and CNS effects. KPV is the alpha-MSH C-terminal tripeptide with NF-kB-mediated anti-inflammatory activity. NAD+ is the master coenzyme for cellular energy metabolism and sirtuin activity.

The blend was designed for multi-pathway research into cognitive, gastrointestinal, and metabolic biology, with the three compounds providing complementary mechanisms relevant to inflammation resolution, neurological function, and cellular energetics. Researchers studying the gut-brain axis and neuro-immune signaling commonly use this combination.

Aeternum Labs supplies the Klow Blend as a single lyophilized vial. Each component is verified to 99%+ purity by HPLC with mass spectrometry confirmation. Full Certificate of Analysis is published for the batch lot.

Mechanism of action

Semax upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and prefrontal cortex. The neurotrophin elevation supports neuron survival, synaptic plasticity, and learning. Additional effects on dopaminergic and serotonergic systems contribute to the broader nootropic profile.

KPV provides the anti-inflammatory arm through NF-kB pathway inhibition. By blocking NF-kB activation, KPV reduces transcription of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1-beta) across multiple cell types including intestinal epithelial cells (relevant to gut research), keratinocytes, and immune cells.

NAD+ anchors the cellular energy and DNA repair layer. As the substrate for sirtuin enzymes and PARP, NAD+ availability rate-limits both gene-expression regulation and damage repair across cellular systems. Restoring NAD+ levels supports mitochondrial function in CNS tissue and elsewhere.

Combined, the three mechanisms address research designs that target the gut-brain axis (KPV gut inflammation + Semax CNS), cognitive aging (Semax BDNF + NAD+ energy + sirtuin activity), and multi-system resilience protocols where inflammation, neurological function, and energy metabolism are studied together.

Research history

Each component has its own development history: Semax in the 1980s at the Russian Academy of Sciences, KPV characterized through 1990s structure-activity research on alpha-MSH, and NAD+ identified in 1906 with modern longevity research interest emerging since 2000.

Multi-system research stacks combining neurotrophic, anti-inflammatory, and energetic compounds reflect a more recent trend in peptide research toward addressing multiple cellular layers simultaneously rather than single-target protocols.

Half-life and pharmacokinetics

Semax can be administered intranasally (reaching cerebrospinal fluid within minutes), subcutaneously, or intramuscularly. KPV has oral bioavailability in addition to subcutaneous use. NAD+ requires injection (IV, IM, or SC) since oral bioavailability is limited by gut degradation.

For the combined blend, subcutaneous administration is the practical default since all three components reach systemic circulation effectively via this route. Tissue distribution favors CNS for Semax effects, gut/skin for KPV, and broad cellular tissue for NAD+.

Typical research doses

Combined research doses typically use 0.3-0.5 mL of the reconstituted blend per administration. Daily dosing during active research windows is common; chronic-effect research uses every-other-day administration.

For gut-brain axis research specifically, dose patterns often align with feeding or circadian schedules to match the natural timing of gut-brain signaling. Cognitive research uses dosing aligned with sleep-wake cycles to match natural BDNF expression patterns.

Reconstitution protocol

Lyophilized peptides require reconstitution with a sterile solvent before any in vitro work. The standard solvent across virtually all research-peptide protocols is bacteriostatic water (sterile water with 0.9% benzyl alcohol), which prevents microbial growth across the typical four-week working window once a vial is opened.

Add the solvent slowly down the inside wall of the vial rather than directly onto the lyophilized cake. Swirl gently until the powder dissolves fully. Do not shake — agitation can denature peptide bonds and reduce assay potency. A clear, particle-free solution should result within thirty to sixty seconds.

Volume calculations are straightforward. For a 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL of the resulting solution contains 0.5 mg of peptide. Researchers planning multi-week protocols should compute their volumes ahead of time and document the lot number against each preparation.

Storage and stability

Sealed lyophilized vials are stable at 0°F (−18°C) for up to twenty-four months in most research literature. Vials should be kept dry, light-protected, and away from temperature fluctuations. Avoid storing peptides in the freezer door, where each open-close cycle introduces thermal stress.

Once reconstituted, store the working solution at 36–46°F (2–8°C). Most lyophilized peptides remain stable in solution for twenty-eight days under refrigeration with bacteriostatic water as the diluent. For protocols longer than four weeks, reconstitute fresh batches as needed rather than extending a single working vial.

Repeated freeze-thaw cycles reduce peptide integrity. If long-term storage of a reconstituted sample is required, aliquot the solution into single-use volumes before freezing so each thaw uses a fresh aliquot.

The NAD+ component is particularly oxidation- and light-sensitive. Light-protected storage and minimal freeze-thaw cycling preserve the active reduced form of NAD+.

Common stack pairings

Klow Blend + BPC-157 (gut-focused research)

BPC-157’s gut barrier protection and tissue repair effects complement KPV’s anti-inflammatory activity in the gut. Combined with Semax’s neurotrophic effects, this stack covers the full gut-brain axis from intestinal barrier to CNS signaling.

Klow Blend + GHK-Cu (longevity research)

GHK-Cu’s gene-expression-resetting profile and NAD+’s sirtuin-pathway support pair well for longevity-focused research. Adding Semax provides the cognitive aging arm.

How it compares

Compared to Semax alone: the Klow Blend adds the gut anti-inflammatory mechanism (KPV) and cellular energy support (NAD+) to Semax’s neurotrophic profile. Standalone Semax is sufficient for cognitive endpoints; the blend is preferred when broader system coverage is wanted.

Compared to NAD+ alone: the Klow Blend adds CNS neurotrophic support (Semax) and anti-inflammatory mechanism (KPV) to NAD+’s cellular energy and sirtuin support. Standalone NAD+ is sufficient for cellular energetics research; the blend addresses multi-system endpoints.

Compared to Glow Blend: Glow Blend targets dermal and tissue research (GHK-Cu + BPC-157 + Glutathione). Klow Blend targets neurological and gut-brain research (Semax + KPV + NAD+). Different tissue focus, complementary rather than competing stack designs.

Frequently asked questions

What is in the Klow Blend?

The Klow Blend contains three compounds: Semax (the Russian-developed ACTH 4-10 analogue), KPV (the alpha-MSH C-terminal tripeptide), and NAD+ (the cellular energy coenzyme). Each component is verified independently to 99%+ purity.

What research is this blend designed for?

The Klow Blend targets neurological, gut-brain axis, anti-inflammatory, and cellular energy research. The three-mechanism coverage (neurotrophic + NF-kB inhibition + sirtuin/NAD+) is particularly suited for multi-system research designs that span CNS, gut, and metabolic endpoints.

How does Klow Blend differ from Glow Blend?

Glow Blend (GHK-Cu + BPC-157 + Glutathione) targets skin and tissue research. Klow Blend (Semax + KPV + NAD+) targets neurological and gut-brain axis research. They are complementary rather than competing — different tissue focus and different mechanism sets.

Why does NAD+ require careful storage in this blend?

NAD+ is particularly sensitive to oxidation and light, more so than typical peptides. The active reduced form (NAD+) interconverts with the oxidized form (NADP+/NADPH systems), and light or oxygen exposure can shift this balance. Strict light-protected storage and minimal freeze-thaw cycling maintain the active NAD+ component across the working window.

What dose ranges are used for this blend in research?

Most published research uses 0.3-0.5 mL of the reconstituted blend per administration, given subcutaneously daily or every other day. Frequency and dose vary substantially depending on the specific research endpoint and observation window.

References

1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression. View source
2. Kannengiesser K, Maaser C, Heidemann J, et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential. View source
3. Imai S, Guarente L (2014). NAD+ and sirtuins in aging and disease. View source